Skip to main content

Table 1 Patient demographics and tumor characteristics

From: Clinical parameters predicting pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer

Variable Total (n = 323) pCR (n = 75) Non-pCR (n = 248) P value
Age (years)a 57 (26–86) 57 (26–86) 58 (32–78) 0.773
Sex 0.342
 Male 174 (53.9) 44 (58.7) 130 (52.4)
 Female 149 (46.1) 31 (41.3) 118 (47.6)
BMI (kg/m2)a 23.6 (17.0–32.2) 24.2 (17.4–31.2) 23.5 (17.0–32.2) 0.386
cT category 0.297
 2 26 (8.0) 7 (9.3) 19 (7.6)
 3 234 (72.5) 58 (77.3) 176 (71.0)
 4 63 (19.5) 10 (13.3) 53 (21.4)
cN category 0.791
 N0 88 (27.2) 21 (28.0) 67 (27.0)
 N1 161 (49.9) 35 (46.7) 126 (50.8)
 N2 74 (22.9) 19 (25.3) 55 (22.2)
cTNM classification 0.867
 II 88 (27.2) 21 (28.0) 67 (27.0)
 III 235 (72.8) 54 (72.0) 181 (73.0)
Distance from the anal verge (cm)a 6 (0–10) 6 (0–10) 6 (0–10) 0.721
Pretreatment CEA (ng/mL)a 3.8 (0.02–31.5) 2.9 (0.06–24.9) 4.2 (0.02–31.5) 0.001
Tumor differentiation 0.679
 Well 24 (7.4) 6 (8.0) 18 (7.3)
 Moderate 250 (77.4) 60 (80.0) 190 (76.6)
 Poor 49 (15.2) 9 (12.0) 40 (16.1)
Type of surgery 0.543
 Low anterior resection 190 (58.8) 40 (53.3) 150 (60.5)
 Abdominoperineal resection 122 (37.8) 32 (42.7) 90 (36.3)
 Hartmann operation 11 (3.4) 3 (4.0) 8 (3.2)
Chemotherapy 0.729
 Capecitabine 267 (82.7) 61 (81.3) 206 (83.1)
 Capecitabine + oxaliplatin 56 (17.3) 14 (18.7) 42 (16.9)
Time interval (day)a 50 (25–105) 57 (35–79) 49 (25–105) <0.001
Radiation dose (Gy)a 50 (38–60) 50 (40–60) 50 (38–60) 0.225
  1. BMI body mass index, CEA carcinoembryonic antigen, pCR pathologic complete response, cT category clinical tumor category, cN category clinical node category, cTNM classification clinical tumor-node-metastasis classification.
  2. aThese values are presented as the median followed by the range in parentheses; other values are presents as numbers of patients followed by the percentage in parentheses.